Craving and addictive potential of esketamine as side effects?

References

• Gaynes BN, Lux L, Gartlehner G, et al. Defining Treatment-Resistant Depression. Depress Anxiety. 2020 Feb;37(2):134–145.
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, et al. STAR*D study team. evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006 Jan;163(1):28–40.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006 Nov;163(11):1905–1917.
   PubMed Web of Science ®Google Scholar
• Witkin JM, Martin AE, Golani LK, et al. Rapid-Acting Antidepressants. Adv Pharmacol. 2019;86:47–96.
   PubMedGoogle Scholar
• Katz MM, Tekell JL, Bowden CL, et al. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology. 2004 Mar;29(3):566–579.
   PubMed Web of Science ®Google Scholar
• Mihaljević S, Pavlović M, Reiner K, et al. Therapeutic mechanisms of ketamine. Psychiatr Danub. 2020;32(3–4):325–333; Autumn-Winter;():. PMID: 33370729.”
   PubMed Web of Science ®Google Scholar
• Andrade C. Ketamine for depression, 3: does chirality matter? J Clin Psychiatry. 2017 Jun;78(6):E674–E677. PMID: 28682536.
   PubMed Web of Science ®Google Scholar
• Kokkinou M, Ashok AH, Howes OD. The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders. Mol Psychiatry. 2018 Jan;23(1):59–69.
   PubMed Web of Science ®Google Scholar
• Liu Y, Lin D, Wu B, et al. Ketamine abuse potential and use disorder. Brain Res Bull. 2016 Sep;126(Pt 1):68–73.
   PubMedGoogle Scholar
• Lally N, Nugent AC, Luckenbaugh DA, et al. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. J Psychopharmacol. 2015 May;29(5):596–607. Epub 2015 Feb 17. PMID: 25691504; PMCID: PMC5116382.
   PubMed Web of Science ®Google Scholar
• Wilkinson ST, Ballard ED, Bloch MH, et al. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry. 2018 Feb 1;175(2):150–158. Epub 2017 Oct 3. PMID: 28969441; PMCID: PMC5794524.
   PubMed Web of Science ®Google Scholar
• Katalinic N, Lai R, Somogyi A, et al. Ketamine as a new treatment for depression: a review of its efficacy and adverse effects. Aust N Z J Psychiatry. 2013 Aug;47(8):710–727. Epub 2013 May 9. PMID: 23661785.
   PubMed Web of Science ®Google Scholar
• Marcantoni WS, Akoumba BS, Wassef M, et al. A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 - January 2019. J Affect Disord. 2020 Dec 1;277:831–841. Epub 2020 Sep 7. PMID: 33065824.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic. March 6, 2019. Www.Fda.Gov/News-Events/Press-Announcements/Fda-Approves-New-Nasal-Spray-Medication-Treatment-Resistant-Depression--available-Only-Certified.
   Google Scholar
• Bozymski KM, Crouse EL, Titus-Lay EN, et al. Esketamine: a novel option for treatment-resistant depression. Ann Pharmacother. 2020 Jun;54(6):567–576.
   PubMed Web of Science ®Google Scholar
• Swainson J, Thomas RK, Archer S, et al. Esketamine for treatment resistant depression. Expert Rev Neurother. 2019 Oct;19(10):899–911.
   PubMedGoogle Scholar
• Daly EJ, Trivedi MH, Janik A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019 Sep 1;76(9):893–903.
   PubMed Web of Science ®Google Scholar
• Fedgchin M, Trivedi M, Daly EJ, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (transform-1). Int J Neuropsychopharmacol. 2019 Oct 1;22(10):616–630.
   PubMed Web of Science ®Google Scholar
• Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019 Jun 1;176(6):428–438. Epub 2019 May 21. Erratum in: Am J Psychiatry. 2019 Aug 1;176(8):669.
   PubMed Web of Science ®Google Scholar
• Ochs-Ross R, Daly EJ, Zhang Y, et al. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-transform-3. Am J Geriatr Psychiatry. 2020 Feb;28(2):121–141.
   PubMed Web of Science ®Google Scholar
• Fu DJ, Ionescu DF, Li X, et al. Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I). J Clin Psychiatry. 2020 May 12;81(3):19m13191.
   PubMed Web of Science ®Google Scholar
• Ionescu DF, Fu DJ, Qiu X, et al. esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II). Int J Neuropsychopharmacol. 2021 Jan 20;24(1):22–31.
   PubMed Web of Science ®Google Scholar
• Wajs E, Aluisio L, Holder R, et al. Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2). J Clin Psychiatry. 2020 Apr 28;81(3):19m12891.
   PubMed Web of Science ®Google Scholar
• Trujillo KA, Smith ML, Sullivan B, et al. The neurobehavioral pharmacology of ketamine: implications for drug abuse, addiction, and psychiatric disorders. ILAR J. 2011;52(3):366–378.
   PubMed Web of Science ®Google Scholar
• Bonnet U. Long-term ketamine self-injections in major depressive disorder: focus on tolerance in ketamine’s antidepressant response and the development of ketamine addiction. J Psychoactive Drugs. 2015 Sep-Oct;47(4):276–285.
   PubMed Web of Science ®Google Scholar
• Kolar D. Addictive potential of novel treatments for refractory depression and anxiety. Neuropsychiatr Dis Treat. 2018 Jun 12;14: 1513–1519.
   PubMed Web of Science ®Google Scholar
• Muetzelfeldt L, Kamboj SK, Rees H, et al. Journey through the K-hole: phenomenological aspects of ketamine use. Drug Alcohol Depend. 2008 Jun 1;95(3):219–229.
   PubMed Web of Science ®Google Scholar
• Bokor G, Anderson PD. Ketamine: an update on its abuse. J Pharm Pract. 2014 Dec;27(6):582–586.
   PubMedGoogle Scholar
• Schak KM, Vande Voort JL, Johnson EK, et al. Potential risks of poorly monitored ketamine use in depression treatment. Am J Psychiatry. 2016 Mar 1;173(3):215–218. PMID: 26926127.
   PubMed Web of Science ®Google Scholar
• FDA Report on Esketamine for Treatment Resistant Depression. 2019; 2019 Apr 9. https://Www.Fda.Gov/downLoads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM630970.Pdf.
   Google Scholar
• Kamaya H, Krishna PR. Ketamine addiction. Anesthesiology. 1987;67(5):861–862.
   PubMed Web of Science ®Google Scholar
• Schifano F, Corkery J, Oyefeso A, et al. Trapped in the “K-hole”: overview of deaths associated with ketamine misuse in the UK (1993-2006). J Clin Psychopharmacol. 2008 Feb;28(1):114–116.
   PubMed Web of Science ®Google Scholar
• Schifano F, Orsolini L, Duccio Papanti G, et al. Novel psychoactive substances of interest for psychiatry. World Psychiatry. 2015 Feb;14(1):15–26.
   PubMed Web of Science ®Google Scholar
• Rivas-Grajales AM, Mathew SJ, Rodgers JJ. A case of intranasal ketamine misuse: considerations for clinical practice. J Psychiatr Pract. 2021 Nov 5;27(6):492–495.
   PubMed Web of Science ®Google Scholar
• Corazza O, Assi S, Schifano F. From “special K” to “special M”: the evolution of the recreational use of ketamine and methoxetamine. CNS Neurosci Ther. 2013 Jun;19(6):454–460.
   PubMed Web of Science ®Google Scholar
• Chen WY, Huang MC, Lin SK. Gender differences in subjective discontinuation symptoms associated with ketamine use. Subst Abuse Treat Prev Policy. 2014;9:39.
   PubMed Web of Science ®Google Scholar
• Chen LY, Chen CK, Chen CH, et al. Association of craving and depressive symptoms in ketamine-dependent patients undergoing withdrawal treatment. Am J Addict. 2020;29(1):43–50.
   PubMed Web of Science ®Google Scholar
• Tang J, Liao Y, He H, et al. Sleeping problems in Chinese illicit drug dependent subjects. BMC Psychiatry. 2015;15:28.
   PubMed Web of Science ®Google Scholar
• Wan LB, Levitch CF, Perez AM, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2015;76:247–252.
   PubMed Web of Science ®Google Scholar
• Wilkinson ST, Katz RB, Toprak M, et al. Acute and longer-term outcomes using ketamine as a clinical treatment at the yale psychiatric hospital. J Clin Psychiatry. 2018 Jul 24;79(4):17m11731.
   PubMed Web of Science ®Google Scholar
• Bryant KA, Altinay M, Finnegan N, et al. Effects of repeated intravenous ketamine in treatment-resistant geriatric depression: a case series. J Clin Psychopharmacol. 2019;39(2):158–161.
   PubMed Web of Science ®Google Scholar
• Gałuszko-Wȩgielnik M, Włodarczyk A, Cubała WJ, et al. case report: repeated series of ketamine infusions in patients with treatment-resistant depression: presentation of five cases. Front Psychiatry. 2021 Dec 2;12: 705190.
   PubMed Web of Science ®Google Scholar
• Feifel D, Dadiomov D, Lee KC. Safety of repeated administration of parenteral ketamine for depression. Pharmaceuticals (Basel). 2020 Jul 13;13(7):151.
   Google Scholar
• Acevedo-Diaz EE, Cavanaugh GW, Greenstein D, et al. Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. J Affect Disord. 2020 Feb 15;263: 568–575.
   PubMed Web of Science ®Google Scholar
• Jonville-Béra AP, Giraudeau B, Autret-Leca E. Reporting of drug tolerance in randomized clinical trials: when data conflict with authors’ conclusions. Ann Intern Med. 2006 Feb 21;144(4):306–307.
   PubMed Web of Science ®Google Scholar
• Smith-Apeldoorn SY, Veraart JKE, Ruhé HG, et al. Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study. BJPsych Open. 2021 Dec 6;8(1):e4.
   PubMed Web of Science ®Google Scholar
• Hashimoto K. Rapid-acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective. Psychiatry Clin Neurosci. 2019 Oct;73(10):613–627.
   PubMed Web of Science ®Google Scholar
• European Medicine Agency (EMA). Assessment report - Spravato [Internet]. 2019. https://www.ema.europa.eu/en/documents/assessment-report/spravato-epar-public-assessment-report_en.pdf
   Google Scholar
• Baudot J, Soeiro T, Tambon M, et al. Safety concerns on the abuse potential of esketamine: multidimensional analysis of a new anti-depressive drug on the market. Fundam Clin Pharmacol. 2021 Dec 15.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders (DSM‐5). 5th edition ed. DC: Arlington (VA); 2013.
   Google Scholar
• Chandler GM, Iosifescu DV, Pollack MH, et al. Research: validation of the massachusetts general hospital antidepressant treatment history questionnaire (ATRQ). CNS Neurosci Ther. 2010;16(5):322–325.
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382–389.
   PubMed Web of Science ®Google Scholar
• Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007 Jul;4(7):28–37.
   PubMedGoogle Scholar
• Flaudias V, Teisseidre F, De Chazeron I, et al. A multi-dimensional evaluation of craving and impulsivity among people admitted for alcohol-related problems in emergency department. Psychiatry Res. 2019 Feb;272:569–571.
   PubMed Web of Science ®Google Scholar
• Sanacora G, Frye MA, McDonald W, et al. American psychiatric association (APA) council of research task force on novel biomarkers and treatments. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017 Apr 1;74(4):399–405.
   PubMed Web of Science ®Google Scholar
• Wang J, Khullar A, McIntyre RS, et al. The drug liking and craving questionnaire (DLCQ) to evaluate addiction risk for ketamine and esketamine. Psychiatry Res Commun. 2022;2(1):100018.
   Google Scholar
• Kalsi SS, Wood DM, Dargan PI. The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerg Health Threats J. 2011 Apr 15;4: 7107.
   PubMedGoogle Scholar
• Quintero GC. Role of nucleus accumbens glutamatergic plasticity in drug addiction. Neuropsychiatr Dis Treat. 2013;9:1499–1512.
   PubMed Web of Science ®Google Scholar
• Persson J. Ketamine in pain management. CNS Neurosci Ther. 2013 Jun;19(6):396–402.
   PubMed Web of Science ®Google Scholar
• Chaudhury D, Liu H, Han MH. Neuronal correlates of depression. Cell Mol Life Sci. 2015 Dec;72(24):4825–4848.
   PubMed Web of Science ®Google Scholar
• Lutz PE, Kieffer BL. Opioid receptors: distinct roles in mood disorders. Trends Neurosci. 2013 Mar;36(3):195–206.
   PubMed Web of Science ®Google Scholar
• Valentino RJ, Volkow ND. Untangling the complexity of opioid receptor function. Neuropsychopharmacology. 2018 Dec;43(13):2514–2520.
   PubMed Web of Science ®Google Scholar
• Carlezon WA Jr, Krystal AD. Kappa-opioid antagonists for psychiatric disorders: from bench to clinical trials. Depress Anxiety. 2016 Oct;33(10):895–906.
   PubMed Web of Science ®Google Scholar
• Kokane SS, Armant RJ, Bolaños-Guzmán CA, et al. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant. Behav Brain Res. 2020 Apr 20;384: 112548.
   PubMed Web of Science ®Google Scholar
• Kalmoe MC, Janski AM, Zorumski CF, et al. Ketamine and nitrous oxide: the evolution of NMDA receptor antagonists as antidepressant agents. J Neurol Sci. 2020 May 15;412: 116778.
   PubMed Web of Science ®Google Scholar
• Duman RS, Li N, Liu RJ, et al. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology. 2012 Jan;62(1):35–41.
   PubMed Web of Science ®Google Scholar
• Scallet AC, Schmued LC, Slikker W Jr, et al. Developmental neurotoxicity of ketamine: morphometric confirmation, exposure parameters, and multiple fluorescent labeling of apoptotic neurons. Toxicol Sci. 2004 Oct;81(2):364–370.
   PubMed Web of Science ®Google Scholar
• Zou X, Patterson TA, Divine RL, et al. Prolonged exposure to ketamine increases neurodegeneration in the developing monkey brain. Int J Dev Neurosci. 2009 Nov;27(7):727–731.
   PubMed Web of Science ®Google Scholar
• Brambrink AM, Evers AS, Avidan MS, et al. Ketamine-induced neuroapoptosis in the fetal and neonatal rhesus macaque brain. Anesthesiology. 2012 Feb;116(2):372–384.
   PubMed Web of Science ®Google Scholar
• Geoffroy H, Noble F. BDNF during withdrawal. Vitam Horm. 2017;104:475–496.
   PubMed Web of Science ®Google Scholar
• Li X, Wolf ME. Multiple faces of BDNF in cocaine addiction. Behav Brain Res. 2015 Feb 15;279: 240–254.
   PubMed Web of Science ®Google Scholar
• Vargas-Perez H, Bahi A, Bufalino MR, et al. BDNF signaling in the VTA links the drug-dependent state to drug withdrawal aversions. J Neurosci. 2014 Jun 4;34(23):7899–7909.
   PubMed Web of Science ®Google Scholar
• Russo SJ, Nestler EJ. The brain reward circuitry in mood disorders. Nat Rev Neurosci. 2013 Sep;14(9):609–625. Epub 2013 Aug 14. Erratum in: Nat Rev Neurosci. 2013 Oct;14(10):736.
   PubMed Web of Science ®Google Scholar
• Nemeroff CB. Ketamine: quo Vadis? Am J Psychiatry. 2018 Apr 1;175(4):297–299.
   PubMed Web of Science ®Google Scholar
• Stahl SM, Pradko JF, Haight BR, et al. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry. 2004;6(4):159–166.
   PubMedGoogle Scholar
• Vento AE, Schifano F, Gentili F, et al. Bupropion perceived as a stimulant by two patients with a previous history of cocaine misuse. Ann Ist Super Sanita. 2013;49:402–405.
   PubMed Web of Science ®Google Scholar
• Mooney ME, Sofuoglu M. Bupropion for the treatment of nicotine withdrawal and craving. Expert Rev Neurother. 2006;6(7):965–981.
   PubMedGoogle Scholar
• Ahmadi J, Sahraian A, Biuseh M. A randomized clinical trial on the effects of bupropion and buprenorphine on the reduction of methamphetamine craving. Trials. 2019;20(1):468.
   PubMedGoogle Scholar
• Ahmadi J, Razeghian Jahromi L. Comparing the effect of buprenorphine and methadone in the reduction of methamphetamine craving: a randomized clinical trial. Trials. 2017;18:259.
   PubMed Web of Science ®Google Scholar
• Ahmadi J, Sefidfard M. Anxiety treatment of opioid dependent patients with buprenorphine: a randomized, double-blind, clinical trial. Indian J Psychol Med. 2017;39:445–449.
   PubMedGoogle Scholar
• Liu YL, Bavato F, Chung AN, et al. Neurofilament light chain as novel blood biomarker of disturbed neuroaxonal integrity in patients with ketamine dependence. World J Biol Psychiatry. 2021 Nov;22(9):713–721.
   PubMed Web of Science ®Google Scholar
• Delfino RS, Del-Porto JA, Surjan J, et al. Comparative effectiveness of esketamine in the treatment of anhedonia in bipolar and unipolar depression. J Affect Disord. 2021 Jan 1;278: 515–518.
   PubMed Web of Science ®Google Scholar
• Pulcu E, Guinea C, Cowen PJ, et al. A translational perspective on the anti-anhedonic effect of ketamine and its neural underpinnings. Mol Psychiatry. 2022 Jan;27(1):81–87.
   PubMed Web of Science ®Google Scholar
• Nogo D, Jasrai AK, Kim H, et al. The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits. Psychopharmacology (Berl). 2022 Mar 15.
   PubMed Web of Science ®Google Scholar